Checkpoint inhibitor therapy
Treatment with immune checkpoint inhibitors for cancer is associated with a high prevalence of multiple immune-related toxicities. Immune-related adverse events (irAEs) can occur anytime during treatment and up to 3 months after treatment. This article discusses checkpoint inhibitor therapy and describes the implementation of a patient education program focused on recognizing immunotherapy irAEs and their toxicities.
Authors
- Shanna Wilson (ORCID: https://orcid.org/0000-0002-4083-7601)
- L. Davis
- Mary Beth Casselbury
Institutions
- Logistics Management Institute (United States) (US)
Publication Details
- Journal
- Nursing
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1097/nsg.0000000000000083
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28